JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Making concave faces convex.

Inadequate projection of the midface skeleton results in midface concavity. Patients with this skeletal morphology tend to have prominent eyes and noses. Lack of skeletal support for the midface soft tissue envelope predisposes to premature cheek descent, resulting in palpebral fissure distortion and lower lid "bags," an appearance of early aging. Concave midfaces can be made convex with two basic maneuvers performed through intraoral and periorbital incisions. Midface skeletal projection can be increased by augmenting the facial skeleton with alloplastic implants. Multiple implants are required to replicate the complex curvature of the midface skeleton and to avoid impingement on the infraorbital nerve. Subperiosteal elevation of the midface soft tissues and repositioning provides cheek fullness and narrows the palpebral fissure while masking eyelid "bags." The resultant midface concavity makes the eyes and nose appear less prominent. This procedure has been a safe and effective treatment for 14 patients treated over a 4-year period.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app